Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma

Arwen Stikvoort, PhD, Subhashis Sarkar, PhD, Renée Poels, BSc, Niels WCJ van de Donk, MD PhD, Sonja Zweegman, MD PhD, Michael E O'Dwyer, MD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2018-99-116403

Published: 2018

Journal Articles

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Subhashis Sarkar, PhD, Sachin Chauhan, MSc, Arwen Stikvoort, PhD, Alessandro Natoni, PhD, John Daly, MSc, Robert Henderson, MB BCh, Tuna Mutis, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3199.

https://doi.org/10.1182/blood-2018-99-118926

Published: 2018

Journal Articles

The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38

Esther Drent, MSc, Renée Poels, BSc, Niels WCJ Van De Donk, Sonja Zweegman, MD PhD, Henk M Lokhorst, Richard WJ Groen, PhD, Tuna Mutis, PhD, Maria Themeli, MD PhD

Blood (2017) 130 (Supplement 1): 3183.

https://doi.org/10.1182/blood.V130.Suppl_1.3183.3183

Published: 2017

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Blood (2017) 130 (Supplement 1): 3124.

https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124

Published: 2017

Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD

Blood (2017) 130 (Supplement 1): 1835.

https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835

Published: 2017

Journal Articles

Lenalidomide Is Highly Effective in Patients with Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplantation and Increases the Frequency of CD4 + FOXP3 + T Cells.

Monique C. Minnema, MD, Michael van der Veer, Tineke Aarts, Maarten Emmelot, Tuna Mutis, PhD, Henk M. Lokhorst, MD

Blood (2007) 110 (11): 2722.

https://doi.org/10.1182/blood.V110.11.2722.2722

Published: 2007

NARROW

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Lenalidomide Is Highly Effective in Patients with Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplantation and Increases the Frequency of CD4 + FOXP3 + T Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only